Hirakawa K - Search Results

1

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.

Kawaji-Kanayama Y, Kobayashi T, Muramatsu A, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida SI, Shimazaki C, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Shimura Y, Horiike S, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Kawaji-Kanayama Y, et al. Among authors: hirakawa k. Cancer Rep (Hoboken). 2022 Feb;5(2):e1476. doi: 10.1002/cnr2.1476. Epub 2021 Jun 14. Cancer Rep (Hoboken). 2022. PMID: 34124862 Free PMC article.

2

[A combined consecutive therapy with fosfomycin and sulbactam/cefoperazone for bacterial infections associated with hematological diseases].

Misawa S, Tsuda S, Taniwaki M, Horiike S, Ariyama Y, Hirakawa K, Ueda Y, Kaneko H, Nakao M, Kashima K, et al. Misawa S, et al. Among authors: hirakawa k. Jpn J Antibiot. 1995 Apr;48(4):514-21. Jpn J Antibiot. 1995. PMID: 7540219 Clinical Trial. Japanese.

3

Neurofibromatosis 1 gene (NF1) mutation is a rare genetic event in myelodysplastic syndrome regardless of the disease progression.

Kaneko H, Horiike S, Nakai H, Ueda Y, Nakao M, Hirakawa K, Yokota S, Taniwaki M, Misawa S, Kashima K. Kaneko H, et al. Among authors: hirakawa k. Int J Hematol. 1995 Apr;61(3):113-6. doi: 10.1016/0925-5710(95)00356-w. Int J Hematol. 1995. PMID: 7599322

4

[Clinical effects of a combination treatment with fosfomycin and clavulanic acid/ticarcillin for infections in patients complicated with hematological disorders].

Hirakawa K, Tsuda S, Misawa S, Ueda Y, Kaneko H, Nakao M, Ariyama Y, Nakai H, Seriu T, Takashima T, et al. Hirakawa K, et al. Jpn J Antibiot. 1994 May;47(5):521-9. Jpn J Antibiot. 1994. PMID: 8051794 Clinical Trial. Japanese.

5

[Efficacy of fluconazole on systemic mycosis associated with hematologic malignancies and a study on diagnostic value of plasma beta-D-glucan levels].

Tsuda S, Misawa S, Horiike S, Hirakawa K, Kuzuyama Y, Nakai H, Seryu T, Takashima T, Taniwaki M, Kashima K, et al. Tsuda S, et al. Among authors: hirakawa k. Jpn J Antibiot. 1993 Oct;46(10):904-11. Jpn J Antibiot. 1993. PMID: 8254892 Japanese.

6

Double mutations of the N-ras gene in a patient with acute myelomonocytic leukemia.

Horiike S, Misawa S, Kaneko H, Nakai H, Ueda Y, Nakao M, Hirakawa K, Taniwaki M, Kashima K. Horiike S, et al. Among authors: hirakawa k. Int J Hematol. 1995 Jun;61(4):205-13. doi: 10.1016/0925-5710(95)00366-z. Int J Hematol. 1995. PMID: 8547609

7

Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.

Kawaji-Kanayama Y, Muramatsu A, Sasaki N, Shimura K, Kiyota M, Fuchida S, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Mizutani S, Nakao M, Kaneko H, Kawata E, Hirakawa K, Takahashi R, Shimazaki C, Uchiyama H, Uoshima N, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Kawaji-Kanayama Y, et al. Among authors: hirakawa k. Int J Hematol. 2022 Mar;115(3):350-362. doi: 10.1007/s12185-021-03262-z. Epub 2022 Jan 24. Int J Hematol. 2022. PMID: 35072907

8

Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma.

Muramatsu A, Kobayashi T, Kawaji-Kanayama Y, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida SI, Shimazaki C, Mizutani S, Tsukamoto T, Shimura Y, Taniwaki M, Teramukai S, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Muramatsu A, et al. Among authors: hirakawa k. Leuk Lymphoma. 2022 Jul;63(7):1678-1685. doi: 10.1080/10428194.2022.2038373. Epub 2022 Feb 11. Leuk Lymphoma. 2022. PMID: 35147475

9

Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: A retrospective study.

Mizuhara K, Kobayashi T, Nakao M, Takahashi R, Kaneko H, Shimura K, Hirakawa K, Uoshima N, Wada K, Kawata E, Isa R, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Yoneda A, Watanabe A, Sotozono C, Kuroda J. Mizuhara K, et al. Among authors: hirakawa k. Cancer Med. 2023 Feb;12(3):3134-3144. doi: 10.1002/cam4.5237. Epub 2022 Sep 12. Cancer Med. 2023. PMID: 36097396 Free PMC article.

10

Neurolymphomatosis of cranial nerves as the responsible lesions for the vocal cord paralysis and facial nerve palsy in a patient with diffuse large B-cell lymphoma.

Inoue Y, Hirakawa K, Hayata H, Nishiyama D, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Kuroda J. Inoue Y, et al. Among authors: hirakawa k. Ann Hematol. 2023 Feb;102(2):481-482. doi: 10.1007/s00277-022-05038-9. Epub 2022 Nov 14. Ann Hematol. 2023. PMID: 36374340 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,461 results

Search Page